Last reviewed · How we verify
Celecoxib + Acetaminohen
Celecoxib selectively inhibits COX-2 to reduce inflammation and pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.
Celecoxib selectively inhibits COX-2 to reduce inflammation and pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects. Used for Acute and chronic pain management, Inflammatory conditions (e.g., osteoarthritis, rheumatoid arthritis).
At a glance
| Generic name | Celecoxib + Acetaminohen |
|---|---|
| Also known as | Cele + Ace |
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | NSAID + analgesic combination |
| Target | COX-2 (celecoxib); prostaglandin synthesis pathway (acetaminophen) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
This is a fixed-dose combination where celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces inflammatory mediators with potentially lower gastrointestinal toxicity compared to non-selective NSAIDs. Acetaminophen works through a different mechanism—inhibiting prostaglandin synthesis centrally and peripherally—providing complementary pain relief and fever reduction. The combination aims to enhance analgesic efficacy while potentially reducing the dose of each individual agent.
Approved indications
- Acute and chronic pain management
- Inflammatory conditions (e.g., osteoarthritis, rheumatoid arthritis)
Common side effects
- Gastrointestinal upset
- Headache
- Dizziness
- Hepatotoxicity (acetaminophen-related)
- Cardiovascular events (celecoxib-related)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Celecoxib + Acetaminohen CI brief — competitive landscape report
- Celecoxib + Acetaminohen updates RSS · CI watch RSS
- Laboratorios Silanes S.A. de C.V. portfolio CI